EC approves Sobi-ADC's Zynlonta for diffuse large B-cell lymphoma
The EC has granted conditional marketing authorisation for Sobi and ADC Therapeutics’ Zynlonta to treat diffuse large B-cell lymphoma.
Source: pharmaceutical-technology.com
Page 4 - Anders Ullman News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Anders Ullman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Anders Ullman Today - Breaking & Trending Today
Swedish Orphan Biovitrum AB: Zynlonta (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma
STOCKHOLM, Dec. 21, 2022 /PRNewswire/ -- Sobi and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of Zynlonta
Source: finanznachrichten.de
Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell l
STOCKHOLM, Dec. 21, 2022 /PRNewswire/ -- Sobi® and ADC Therapeutics SA today announced that the European...
Source: europapress.es
Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma
/PRNewswire/ -- Sobi® and ADC Therapeutics SA today announced that the European Commission (EC) has granted conditional marketing authorisation for the use of...
Source: prnewswire.com
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Approval triggers $50 million milestone payment to ADC Therapeutics ... | December 21, 2022
Source: marketscreener.com